Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2878 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Nov 2026, 03:15 UTC
2878
Studies in scope
industry-sponsored, all four open statuses
1386
Recruiting now
open to new participants
546
Lead sponsors
across recruiting studies
Top sites
London 2026 Manchester 676 Birmingham 483 Glasgow 436 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca139 Merck Sharp & Dohme LLC97 Hoffmann-La Roche82 Novartis Pharmaceuticals72 Janssen Research & Development, LLC70
Site city
London2026 Manchester676 Birmingham483 Glasgow436 Cambridge425
All 437 cities
Target enrolment
to

Trials with a site in London

2026 of 2878 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Amgen
Phase 1/2
329
London, Sutton
2022-02-01
Active, closed
Gene Therapy Study for Children With CLN5 Batten Disease
NCT05228145Neuronal Ceroid Lipofuscinosis CLN5
Neurogene Inc.
Phase 1/2
6
London
2022-01-31
Active, closed
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
NCT05234190Rejection; Transplant, Liver, Liver Failure, Liver Diseases
Quell Therapeutics Limited
Phase 1/2
33
Birmingham, Cambridge, London
2022-01-21
Active, closed
OncoBeta Therapeutics
Not applicable
210
London
2022-01-17
Active, closed
Microvention-Terumo, Inc.
Observational
206
Edinburgh, Liverpool, London
2022-01-14
Recruiting
The "Global Paradise System" Registry
NCT05027685Hypertension
ReCor Medical, Inc.
Observational
3,000
Bournemouth, Canterbury, Cardiff, Dudley, Glasgow, Hull, London, Newcastle
2022-01-13
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol
2022-01-13
Active, closed
Noema Pharma AG
Phase 2/3
166
London
2022-01-11
Recruiting
Nuvalent Inc.
Phase 1/2
359
London, Manchester
2022-01-04
Active, closed
Boston Scientific Corporation
Not applicable
500
Guildford, Cardiff, Belfast, Bristol, London, Norwich, Plymouth
2021-12-21
Active, closed
ITM Solucin GmbH
Phase 3
259
London
2021-12-21
Recruiting
Occlutech International AB
Observational
255
London
2021-12-20
Active, closed
Eli Lilly and Company
Phase 3
152
London, Nottingham, Wolverhampton
2021-12-20
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals, Inc.
Phase 3
194
Cambridge, Manchester, London
2021-12-20
Recruiting
Takeda
Phase 2
135
Boston, Leeds, London
2021-12-16
By invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases
DrugsKITE-197·SPRX002·KITE-753·Tecartus
Kite, A Gilead Company
Observational
1,500
London
2021-12-15
Active, closed
GlaxoSmithKline
Phase 2
366
Cottingham, Liverpool, London, Plymouth
2021-12-14
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab
Exelixis
Phase 1
1,394
Cambridge, London, Middlesex
2021-12-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
East Sussex, Cambridge, Truro, Kendal, Dundee, Leicester, London, Cardiff
2021-12-13
Active, closed
Alnylam Pharmaceuticals
Observational
207
London
2021-12-13
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Edinburgh, Glasgow, Guildford, London, Newcastle upon Tyne, Nottingham
2021-12-10
Recruiting
UCB Biopharma SRL
Phase 3
350
Birmingham, Cardiff, Glasgow, London, Oxford, Salford
2021-12-07
Active, closed
Sanofi
Phase 2
22
Leeds, London
2021-12-07
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
325
Birmingham, Bristol, Glasgow, London, Manchester, Sheffield
2021-12-06
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Bristol, Edinburgh, Leeds, London, Peterborough, Sheffield
2021-12-02
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
London, Manchester
2021-12-01
Recruiting
H. Lundbeck A/S
Phase 3
600
Edinburgh, Great Yarmouth, Glasgow, London
2021-12-01
Recruiting
Blueprint Medicines Corporation
Phase 2/3
534
Cardiff, Birmingham, London, Oxford, Plymouth
2021-11-30
Active, closed
Agios Pharmaceuticals, Inc.
Phase 3
258
London
2021-11-30
Active, closed
AstraZeneca
Phase 3
145
London, Manchester
2021-11-19
Active, closed
Hoffmann-La Roche
Phase 3
660
Blackpool, GB Manchester, Hull, Leeds, Leicester, London
2021-11-18
Active, closed
Janssen Pharmaceutica N.V., Belgium
Observational
256
Bristol, London, Maidstone, Nottingham, Surrey
2021-11-18
Active, closed
argenx
Phase 3
173
Coventry, London, Penzance
2021-11-17
Active, closed
Gilead Sciences
Phase 3
603
Birmingham, Colchester, Glasgow, Leeds, Leicester, London, Manchester
2021-11-17
Recruiting
Pfizer
Phase 3
245
Newcastle upon Tyne, London, Birmingham
2021-11-17
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Cardiff, Edinburgh, London, Manchester
2021-11-17
Recruiting
ModernaTX, Inc.
Phase 1/2
50
Manchester, Birmingham, London
2021-11-09
Recruiting
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
DrugBezuclastinib
Cogent Biosciences, Inc.
Phase 2
140
Leeds, London
2021-11-09
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216Acute Stroke, Ischemic Stroke, Stroke
DiaMedica Therapeutics Inc
Phase 2/3
728
Exeter, Newcastle upon Tyne, Cambridge, London, Stoke-on-Trent, Kirkcaldy, Leeds, Middlesbrough
2021-11-07
Active, closed
Merck Sharp & Dohme LLC
Phase 2
60
London
2021-11-02
Active, closed
Amgen
Phase 3
303
London
2021-11-02
Active, closed
Tenaya Therapeutics
Observational
200
Glasgow, London
2021-11-01
Recruiting
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
NCT05104515Prostate Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
Oxford Vacmedix UK Ltd.
Phase 1
36
London, Manchester, Oxford
2021-11-01
Recruiting
Mercator MedSystems, Inc.
Phase 2
80
London
2021-10-29
Active, closed
AstraZeneca
Phase 3
148
Leicester, London
2021-10-28
Active, closed
Hoffmann-La Roche
Phase 3
478
Cornwall, London, Nottingham, Torquay
2021-10-27
Active, closed
Kite, A Gilead Company
Phase 1/2
247
London
2021-10-27
Active, closed
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
NCT04988386Amyloid Cardiomyopathy, Transthyretin-Related
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
389
London
2021-10-27
Active, closed
argenx
Phase 2/3
15
London, Manchester, Oxford
2021-10-26
Active, closed
Hoffmann-La Roche
Phase 3
303
Cambridge, Leeds, London, Manchester
2021-10-26
Recruiting
Hoffmann-La Roche
Phase 1
542
Cambridge, Cardiff, London, Manchester, Sutton
2021-10-22
By invitation
Blood Testing at Entia
NCT05580055Healthy, Blood Cell Count
Entia Ltd
Observational
100
London
2021-10-22
Active, closed
JOTEC GmbH
Observational
108
Cottingham, London, Newcastle
2021-10-20
Recruiting
AstraZeneca
Phase 1/2
460
Cambridge, Cardiff, London
2021-10-18
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Birmingham, Cambridge, London, Sheffield, Southampton
2021-10-18
Active, closed
AstraZeneca
Phase 3
732
Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham
2021-10-18
Active, closed
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
NCT05059262Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse
DrugVimseltinib
Deciphera Pharmaceuticals, LLC
Phase 3
123
London
2021-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Blackpool, Dundee, London, Oxford, Plymouth, Sutton
2021-10-14
Active, closed
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
NCT04907240Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms
W.L.Gore & Associates
Observational
614
Bristol, Glasgow, London
2021-10-09
Active, closed
UniQure Biopharma B.V.
Phase 1/2
14
Cardiff, London
2021-10-07
Active, closed
Hoffmann-La Roche
Phase 2
176
Edinburgh, London
2021-10-07
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
London, Nottingham, Oxford
2021-10-06
Active, closed
Safe and Timely Antithrombotic Removal (STAR) Registry
NCT05077124Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical, Blood Loss, Postoperative
CytoSorbents, Inc
Observational
1,000
Blackpool, London, Sheffield
2021-09-30
Active, closed
Pfizer
Phase 3
77
London, Newcastle upon Tyne, Truro
2021-09-29
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
Nurix Therapeutics, Inc.
Phase 1
345
Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford
2021-09-29
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 1/2
82
London
2021-09-27
Active, closed
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075Conventional Chondrosarcoma
DrugINBRX-109
Inhibrx Biosciences, Inc
Phase 2
206
London, Manchester, Oxford
2021-09-23
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Southampton, Birmingham, Belfast, London, Newcastle upon Tyne, Nottingham
2021-09-22
Active, closed
Janssen Research & Development, LLC
Phase 1
166
London, Manchester, Oxford, Surrey
2021-09-22
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Newcastle upon Tyne, Cambridge, Leicester, London, Salford
2021-09-20
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Recruiting
BeOne Medicines
Phase 1/2
246
Headington, London, Sutton
2021-09-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
2,000
East Sussex, Bristol, London, Manchester
2021-09-15
Active, closed
Bristol-Myers Squibb
Phase 3
338
Cannock, Hull, London
2021-09-15
Recruiting
Colibri Transcatheter Aortic Heart Valve System Study
NCT04029844Severe Aortic Stenosis
Colibri Heart Valve LLC
Not applicable
30
Brighton, London
2021-09-15
Active, closed
Hoffmann-La Roche
Phase 1/2
42
London, Manchester, Newcastle upon Tyne
2021-09-14
Active, closed
Albireo, an Ipsen Company
Phase 3
62
Birmingham, London
2021-09-03
Active, closed
Immunome, Inc.
Phase 2/3
198
Edinburgh, Cambridge, London, Manchester
2021-09-01
Active, closed
Sanofi
Phase 3
17
London, Manchester
2021-09-01
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Leicester, London, Nottingham, Preston
2021-08-27
Active, closed
iSTAR Medical
Not applicable
975
East Grinstead, London, York
2021-08-19
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Birmingham, Bristol, Leeds, London, Manchester, Surrey
2021-08-19
Active, closed
Inventiva Pharma
Phase 3
1,000
London, Manchester, Newcastle upon Tyne, Nottingham, Preston, Sheffield, Surrey Quays, Glasgow
2021-08-19
Active, closed
Long-Term Follow-up of Subjects Who Were Treated With ST-920
NCT05039866Fabry Disease, Fabry Disease, Cardiac Variant
Sangamo Therapeutics
Observational
32
Cambridge, London
2021-08-16
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Bradford, Cambridge, London, Londonderry, North Shields, Portadown, Sheffield, Stevenage
2021-08-14
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
DrugSparsentan
Travere Therapeutics, Inc.
Phase 2
67
Bristol, Glasgow, Liverpool, London, Manchester
2021-08-12
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Cambridge, London, Glasgow
2021-08-12
Active, closed
Pfizer
Phase 3
118
London, Birmingham
2021-08-12
Active, closed
Tanabe Pharma America, Inc.
Phase 3
286
Manchester, London
2021-08-10
Active, closed
AstraZeneca
Phase 3
712
London
2021-08-05
Active, closed
Boston Scientific Corporation
Phase 4
544
Cardiff, London, Middlesex
2021-08-02
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Glasgow, Newcastle upon Tyne, London
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Leeds, London
2021-07-27
Recruiting
Genentech, Inc.
Phase 1
186
London, Sutton
2021-07-26
Active, closed
AbbVie
Phase 3
132
Exeter, Plymouth, London
2021-07-24
Active, closed
Biogen
Phase 3
562
London, Doncaster, Cannock
2021-07-16
Active, closed
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
Avacta Life Sciences Ltd
Phase 1
158
Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield
2021-07-16
Active, closed
Bristol-Myers Squibb
Phase 3
729
London, Bradford, Hull, Liverpool, Manchester
2021-07-15
Active, closed
Hoffmann-La Roche
Phase 3
451
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2021-07-14
Active, closed
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
NCT04554914Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
DrugTabelecleucel
Pierre Fabre Medicament
Phase 2
190
Birmingham, London
2021-07-14
Active, closed
VectivBio AG
Phase 3
158
Harrow, London, Salford
2021-07-13
Active, closed
Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation
NCT04788888Symptomatic Severe Aortic Stenosis
Abbott Medical Devices
Not applicable
434
Swansea, Belfast, Leeds, London
2021-07-13
Recruiting
Boehringer Ingelheim
Phase 1
554
London, Sutton
2021-07-02
Recruiting
H. Lundbeck A/S
Phase 3
285
Exeter, Edinburgh, Great Yarmouth, Glasgow, London
2021-06-30
Active, closed
AstraZeneca
Phase 3
315
Blackpool, Cambridge, London, Manchester, Newport, Nottingham, Portsmouth, Reading
2021-06-30
Recruiting
Corcym S.r.l
Observational
2,150
Birmingham, Bristol, London
2021-06-29
Active, closed
GlaxoSmithKline
Phase 3
40
Bath, Brighton, Cardiff, Coventry, Edinburgh, Leeds, London, Maidstone
2021-06-28
Recruiting
Penumbra Inc.
Observational
1,500
Brighton, Cardiff, London
2021-06-25
Active, closed
Neurocrine Biosciences
Phase 3
103
London
2021-06-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Aberdeen, Birmingham, Cambridge, Dorset, Glasgow, Kent, Leeds, London
2021-06-24
Recruiting
Electroporation for Cancer Treatment Real World Registry
NCT04929912Skin Cancer, Gastrointestinal Cancer
Mirai Medical
Observational
1,000
London
2021-06-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Truro, Leicester, London, Manchester, Blackpool, Londonderry
2021-06-18
By invitation
Philips Clinical & Medical Affairs Global
Not applicable
3,212
Southampton, Cardiff, Bournemouth, London
2021-06-17
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
89
London
2021-06-14
Active, closed
Sanofi
Observational
16
London, Manchester
2021-06-10
Active, closed
Novartis Pharmaceuticals
Phase 3
1,144
Sutton, Belfast, Cambridge, Glasgow, London, Middlesbrough
2021-06-09
Active, closed
AstraZeneca
Phase 3
367
Doncaster, Leeds, London
2021-06-08
Active, closed
Daiichi Sankyo
Phase 2
155
London, Nottingham, Oxford
2021-06-03
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
54
London
2021-06-01
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
London, Oxford, Sheffield
2021-05-26
Active, closed
Daiichi Sankyo
Phase 3
490
Birmingham, Cambridge, Cardiff, Dundee, Glasgow, Liverpool, London, Manchester
2021-05-21
Recruiting
GE Healthcare
Phase 1/2
54
Bristol, London
2021-05-20
Active, closed
Savara Inc.
Phase 3
164
London
2021-05-19
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
Cardiff, Leeds, Liverpool, London, Manchester, Oxfordshire, Plymouth
2021-05-19
Active, closed
Pfizer
Phase 3
599
Exeter, Maidstone, Preston, Edinburgh, Glasgow, Sheffield, Birmingham, London
2021-05-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Cambridge, Glasgow, London, Newcastle upon Tyne, Sheffield
2021-05-12
Active, closed
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Active, closed
Alfasigma S.p.A.
Observational
1,304
Aberdeen, Barnet, Coventry, Doncaster, Dundee, Edinburgh, Liverpool, London
2021-05-11
Active, closed
ALX Oncology Inc.
Phase 2
172
London
2021-05-10
Active, closed
AstraZeneca
Phase 3
893
Guildford, London, Londonderry, Taunton, York
2021-05-10
Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103Metastatic Non Small Cell Lung Cancer
DrugLifileucel
Iovance Biotherapeutics, Inc.
Phase 2
170
Chelsea, London, Manchester, Birmingham
2021-05-07
By invitation
Cytokinetics
Phase 2/3
900
Birmingham, Dundee, Glasgow, Liverpool, London, Oxford
2021-05-06
Active, closed
Hoffmann-La Roche
Phase 2
586
Dundee, London, Newcastle, Oxford, Peterborough, Plymouth
2021-05-05
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Blackpool, Brighton, Cambridge, Cheltenham, London, Manchester, Northwood, Preston
2021-05-04
Active, closed
Abbott Medical Devices
Observational
200
London
2021-05-04
Recruiting
Debiopharm International SA
Phase 1
464
London
2021-04-30
Recruiting
RECORDATI GROUP
Phase 2
12
Liverpool, London
2021-04-28
Active, closed
AstraZeneca
Phase 3
1,157
Edinburgh, Guildford, London, Manchester, Swansea, Taunton
2021-04-26
Active, closed
Hoffmann-La Roche
Phase 3
557
Birmingham, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2021-04-26
Recruiting
Alnylam Pharmaceuticals
Observational
150
Cardiff, London
2021-04-26
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 2
141
London, Newcastle upon Tyne
2021-04-22
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
DrugPhase 2
enGene, Inc.
Phase 1/2
350
London
2021-04-22
Active, closed
Sarepta Therapeutics, Inc.
Observational
205
London, Newcastle upon Tyne
2021-04-22
Active, closed
Contura
Observational
201
London, Truro
2021-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Torquay, London
2021-04-21
Active, closed
Novartis Pharmaceuticals
Phase 2
236
West Midlands, London, Manchester
2021-04-19
Recruiting
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
NCT04580420Primary Hyperoxaluria Type 1, End Stage Renal Disease
DrugDcr-Phxc
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 2
28
London
2021-04-15
Recruiting
ModernaTX, Inc.
Phase 1/2
77
Birmingham, London, Manchester
2021-04-15
Active, closed
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Active, closed
Takeda
Phase 3
77
London
2021-04-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Cambridge, London, Northwood
2021-04-14
Active, closed
Abiomed Inc.
Not applicable
1,252
London
2021-04-13
Active, closed
NS Pharma, Inc.
Phase 3
74
Birmingham, Glasgow, London
2021-04-13
Active, closed
Geron Corporation
Phase 3
327
London, Oxford
2021-04-12
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Edinburgh, Cardiff, Boston, Cambridge, Liverpool, London, Oxford
2021-04-09
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Bristol, Nottingham, Windsor, London, Oxford, Newmarket, Sutton, Manchester
2021-04-05
Active, closed
ALX Oncology Inc.
Phase 2
189
London, Sutton
2021-04-02
Recruiting
Boston Scientific Corporation
Observational
12,500
London, Manchester
2021-03-31
Recruiting
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
NCT04786262Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
DrugZimislecel
Vertex Pharmaceuticals Incorporated
Phase 3
57
Headington, Edinburgh, London, Newcastle upon Tyne
2021-03-29
Recruiting
Prospective Study of White Blood Cells
NCT04838171Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver
Quell Therapeutics Limited
Observational
10
London
2021-03-24
Recruiting
Bristol-Myers Squibb
Phase 3
153
London, Connor Downs
2021-03-23
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
London, Oxford, Sutton
2021-03-18
Active, closed
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis
NCT04713475GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
Gemma Biotherapeutics
Phase 1/2
26
London
2021-03-17
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
Sheffield, London
2021-03-15
Active, closed
Hoffmann-La Roche
Phase 1/2
241
London
2021-03-15
Active, closed
Janssen Research & Development, LLC
Phase 1
140
London, Manchester, Surrey
2021-03-12
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
London, Oxford, Boston, Liverpool, Newcastle upon Tyne
2021-03-11
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Aberdeen, Truro, Plymouth, Cottingham, London, Norwich, Swansea, Edinburgh
2021-03-09
Active, closed
BioNTech SE
Phase 2
327
Bebington, Birmingham, Cardiff, Cottingham, Dorchester, Glasgow, London, Manchester
2021-03-08
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Bristol, Cardiff, Glasgow, London
2021-03-04
Active, closed
LifeSprout, Inc.
Not applicable
118
London
2021-03-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
747
Aberdeen, Bath, Nottingham, Southend, London, Northwood, Taunton, Swansea
2021-02-25
Active, closed
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Phase 3
455
London, Sutton
2021-02-25
Active, closed
Hoffmann-La Roche
Phase 3
270
Glasgow, Leeds, London, Manchester, Nottingham
2021-02-23
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
London, Birmingham, Hampshire
2021-02-23
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
DrugsNavtemadlin·Acalabrutinib
Kartos Therapeutics, Inc.
Phase 1/2
84
Leeds, London, Southampton
2021-02-23
Recruiting
Biosense Webster, Inc.
Observational
8,000
Leicester, London
2021-02-22
Active, closed
M.A. Med Alliance S.A.
Not applicable
723
Frimley, Leicester, London, Redhill
2021-02-08
Recruiting
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04901936Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
DrugPegcetacoplan
Apellis Pharmaceuticals, Inc.
Phase 2
12
London
2021-02-04
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Birmingham, London, Manchester
2021-02-02
Active, closed
Forma Therapeutics, Inc.
Phase 3
450
Leicester, London, Oxford, Sheffield
2021-01-29
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
DrugsIrinotecan·Gemcitabine
Artios Pharma Ltd
Phase 1/2
542
London, Manchester, Glasgow
2021-01-27
Recruiting
BioInvent International AB
Phase 1/2
250
Birmingham, Leicester, London, Manchester, Southampton
2021-01-25
By invitation
A Long-term Follow-up Study in Participants Who Received CTX001
NCT04208529Beta-Thalassemia, Thalassemia, Sickle Cell Disease, Hematologic Diseases
DrugExa-cel
Vertex Pharmaceuticals Incorporated
Phase 3
160
London
2021-01-20
Active, closed
Hoffmann-La Roche
Phase 2
920
Glasgow, London, Manchester
2021-01-18
Recruiting
Pfizer
Phase 3
2,100
Leicester, London
2021-01-15
Active, closed
Pfizer
Phase 3
257
London, Swansea
2021-01-15
Active, closed
Genmab
Phase 3
483
Birmingham, London, Norwich, Nottingham, Plymouth, Southampton, Sutton, Truro
2021-01-13
Active, closed
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
DrugsTucatinib·Herceptin·Fulvestrant·Trastuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
217
London, Sutton
2021-01-11
Active, closed
Galderma R&D
Phase 3
500
Dudley, Glasgow, London, Newcastle upon Tyne
2021-01-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Bristol, Cottingham, Glasgow, London, Sutton, Leicester, Manchester
2021-01-10
Recruiting
Real-Life Chronic Rhinosinusitis Outcome Registry
NCT04670172Chronic Rhinosinusitis (Diagnosis)
Change Accelerator in Respiratory Care
Observational
4,550
London
2021-01-01
Active, closed
Replimune, Inc.
Phase 1
123
Bebington, London, Oxford
2020-12-29
Active, closed
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
Daiichi Sankyo
Phase 3
605
London, Manchester, Middlesbrough
2020-12-21
Active, closed
Verastem, Inc.
Phase 2
225
Edinburgh, Glasgow, London, Manchester, Sutton
2020-12-21
Active, closed
Novartis Pharmaceuticals
Phase 2
17
London
2020-12-18
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
Neurocrine Biosciences
Phase 3
182
Cardiff, London, Manchester, Salford
2020-12-16
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Bristol, Hertford, Leicester, London, Salford
2020-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Aberdeen, Dundee, Taunton, London, Manchester
2020-12-08
Active, closed
GlaxoSmithKline
Phase 2/3
758
Cardiff, Edinburgh, London, Manchester
2020-12-08
Active, closed
Amgen
Phase 3
135
Leeds, London, Newcastle, Oxford
2020-12-04
Active, closed
MeiraGTx Ocular UK Ltd
Phase 3
97
Edinburgh, Glasgow, Leeds, London
2020-12-04
Active, closed
Hoffmann-La Roche
Phase 3
769
London, Newcastle upon Tyne, Plymouth
2020-12-03
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Birmingham, Edinburgh, Kent, Leicester, London, Manchester, Surrey
2020-12-02
Active, closed
Hoffmann-La Roche
Phase 2
303
Harlow, London, Nottingham, Peterborough
2020-11-27
Active, closed
Science Corporation
Not applicable
38
London
2020-11-24
Active, closed
AstraZeneca
Phase 3
957
Cambridge, Dundee, Glasgow, Leicester, London, Manchester, Oxford, Surrey
2020-11-17
Active, closed
UCB Biopharma SRL
Phase 1
19
London, Southampton
2020-11-16
Active, closed
The ENCIRCLE Trial
NCT04153292Mitral Regurgitation, Mitral Valve Insufficiency
Edwards Lifesciences
Not applicable
786
London
2020-11-12
Active, closed
Prevail Therapeutics
Phase 1/2
35
London
2020-11-09
Active, closed
Pfizer
Phase 3
114
Newcastle upon Tyne, Liverpool, London
2020-11-05
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
281
Glasgow, London
2020-11-03
Recruiting
Study to Evaluate the Safety and Tolerability of EP0042
NCT04581512Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
DrugsAzacitidine·Venetoclax
Ellipses Pharma
Phase 1/2
70
London, Manchester
2020-11-02
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
London, Newcastle upon Tyne
2020-10-29
Active, closed
Hoffmann-La Roche
Phase 3
985
Glasgow, London, Nottingham, Swansea
2020-10-26
Active, closed
Bayer
Phase 3
774
Reading, Colchester, London, Bebington, Scunthorpe, Glasgow, Cardiff, Llanelli
2020-10-20
Active, closed
Exelixis
Phase 3
575
London, Surrey Quays, Taunton, Blackburn, Northwood, Swansea
2020-10-19
Active, closed
Janssen Research & Development, LLC
Phase 3
308
Edinburgh, London, Sutton
2020-10-13
Active, closed
BioMarin Pharmaceutical
Phase 2
20
London, Sheffield
2020-10-10
Active, closed
Hoffmann-La Roche
Phase 3
992
Brighton, Leicester, London, Maidstone, Peterborough, Plymouth, Sutton, Truro
2020-10-09
Active, closed
Hoffmann-La Roche
Phase 3
210
Leeds, London
2020-10-08
Active, closed
AstraZeneca
Phase 3
370
London, Manchester, Newcastle upon Tyne, Sutton
2020-10-02
Active, closed
GlaxoSmithKline
Phase 3
302
London, Plymouth, Southampton, Stoke-on-Trent, Sutton
2020-10-01
Recruiting
Smith & Nephew, Inc.
Observational
400
Manchester, Harpenden, Brighton, Burnley, Grantham, London, Bath, Hertford
2020-10-01
Active, closed
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
NCT04093349Pompe Disease, Pompe Disease (Late-onset), Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II
Spark Therapeutics, Inc.
Phase 1/2
4
Birmingham, London, Salford
2020-10-01
Active, closed
Hoffmann-La Roche
Phase 3
190
London
2020-09-30
Active, closed
Janssen Research & Development, LLC
Phase 3
1,074
Edinburgh, London, Manchester, Nottingham, Sutton
2020-09-30
Active, closed
AbbVie
Phase 3
527
Cambridge, Exeter, Edinburgh, London, Southampton, Stevenage, Glasgow, Nottingham
2020-09-30
Active, closed
Ipsen
Phase 3
161
Newcastle upon Tyne, Belfast, Camberley, Cambridge, Hull, London, Nottingham, Plymouth
2020-09-24
Recruiting
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
DrugAtirmociclib
Pfizer
Phase 1/2
430
Edinburgh, London, Manchester
2020-09-23
Active, closed
argenx
Phase 2
229
London, Oxford, Sheffield
2020-09-18
Active, closed
Janssen Research & Development, LLC
Phase 2
194
London, Sothampton, Sutton
2020-09-17
Recruiting
Epygenix
Phase 3
150
Cardiff, London, Sheffield
2020-09-15
Active, closed
AbbVie
Phase 3
531
Plymouth, Poole, London, Oxford, Cardiff, Aberdeen, Birmingham, Bristol
2020-09-10
Active, closed
AbbVie
Phase 3
330
London, Lincoln, Great Yarmouth, Birmingham, Edinburgh, Newcastle upon Tyne
2020-08-31
Recruiting
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
NCT04421820Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
DrugBOLD-100
Bold Therapeutics, Inc.
Phase 1/2
220
Cardiff, Dundonald, London, Sutton
2020-08-28
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
125
London
2020-08-25
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
240
Birmingham, London, Sandwich
2020-08-20
Active, closed
Pfizer
Phase 3
77
London
2020-08-18
Active, closed
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
477
London, Manchester, Sutton
2020-08-18
Active, closed
Hoffmann-La Roche
Phase 1/2
237
London, Manchester, Newcastle upon Tyne, Nottingham
2020-08-12
Recruiting
Eisai Inc.
Phase 1/2
182
Belfast, Glasgow, Manchester, Preston, London, Northwood, Cardiff, Sutton
2020-08-06
Active, closed
AstraZeneca
Phase 3
185
Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton
2020-08-04
Active, closed
Medtronic
Observational
2,200
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2020-08-01
Active, closed
Medtronic
Observational
2,200
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2020-08-01
Active, closed
Genentech, Inc.
Phase 1
498
Birmingham, Cardiff, London, Manchester
2020-07-29
Active, closed
AstraZeneca
Phase 3
866
Cambridge, Cardiff, Edinburgh, Guildford, Leeds, London, Manchester, Northwood
2020-07-24
Active, closed
AstraZeneca
Phase 3
134
London
2020-07-20
Active, closed
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT04561362Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms
DrugsZelenectide pevedotin·Keytruda·Pembrolizumab
BicycleTx Limited
Phase 1/2
329
London, Manchester
2020-07-17
Active, closed
GlaxoSmithKline
Phase 3
242
Basingstoke, Glasgow, London, Newcastle upon Tyne, Nottingham, Plymouth, Reading Berkshire, Southampton
2020-07-14
Active, closed
Eisai Inc.
Phase 3
1,400
Bristol, Glasgow, London
2020-07-14
Active, closed
Celgene
Phase 2
276
London, Manchester
2020-07-14
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
160
Leeds, Birmingham, London
2020-07-13
Active, closed
RETHINK REFLUX Registry
NCT04253392Gastroesophageal Reflux
Ethicon Endo-Surgery
Observational
500
Epsom, London, Royal Tunbridge Wells
2020-07-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Sheffield, London, London-Camden, Southampton, Leeds, Manchester
2020-07-06
Active, closed
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
DrugTemozolomide
Sapience Therapeutics
Phase 1/2
125
Edinburgh, Glasgow, Leeds, London
2020-07-01
Active, closed
Actelion
Phase 3
935
London, Newcastle upon Tyne, Sheffield
2020-06-30
Active, closed
SAPIEN 3 Ultra System PMCF
NCT04555967Aortic Valve Stenosis
Edwards Lifesciences
Observational
200
Belfast, London
2020-06-30
Active, closed
Eli Lilly and Company
Phase 3
996
Cambridge, London, Cardiff
2020-06-22
Active, closed
Eli Lilly and Company
Phase 3
1,736
Motherwell, London, Guildford, Birmingham
2020-06-19
Active, closed
Sanofi
Phase 3
337
Bournemouth, London, Leicester, Southampton
2020-06-16
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Birmingham, Bristol, Cardiff, London, Manchester, Newcastle upon Tyne
2020-06-12
Active, closed
Epizyme, Inc.
Phase 3
599
Edinburgh, London, Bebington, Cornwell, Glasgow, Middlesex
2020-06-11
Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
DrugsSigvotatug vedotin·Keytruda·Cisplatin·Carboplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
1,006
Sutton, Birmingham, London
2020-06-08
Active, closed
Autolus Limited
Phase 1/2
153
Cambridge, London, Manchester, Glasgow, Newcastle upon Tyne, Birmingham, Bristol
2020-06-03
Active, closed
AstraZeneca
Phase 2
452
Cambridge, Dundee, London, Manchester, Sutton
2020-06-03
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
London, Maidstone, Manchester, Oxford, Southampton
2020-05-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Rhyl, Torquay, Preston, London, Nottingham, Darlington
2020-05-19
Active, closed
AstraZeneca
Phase 3
818
Aberdeen, Bournemouth, Bristol, Cardiff, Cheltenham, London, Manchester, Sutton
2020-04-16
Active, closed
GlaxoSmithKline
Phase 3
325
Airdrie, Dundee, Edinburgh, London, Nottingham, Oxford, Plymouth, Stoke-on-Trent
2020-04-02
Active, closed
Eisai Inc.
Phase 1
31
London, Sutton
2020-04-01
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Glasgow, London, Oxford, Plymouth, Preston, Sheffield, Southampton
2020-03-30
Recruiting
Richmond Research Institute
Observational
2,500
London
2020-03-16
Recruiting
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
NCT04094610Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
DrugRepotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2
75
Liverpool, Birmingham, Cardiff, Glasgow, London
2020-03-12
Active, closed
First-in-Human Study of ICT01 in Patients With Advanced Cancer
NCT04243499Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer
ImCheck Therapeutics, an Ipsen company
Phase 1/2
293
Glasgow, London
2020-03-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Cambridge, Edinburgh, Glasgow, London, Sutton, Gillingham, Manchester
2020-02-27
Active, closed
Immunocore Ltd
Phase 1/2
410
London, Oxford, Glasgow, Liverpool, Manchester, Surrey Quays
2020-02-25
Active, closed
Eli Lilly and Company
Phase 3
58
Bristol, Liverpool, London, Oxford, Sheffield
2020-02-12
Active, closed
Loxo Oncology, Inc.
Phase 3
291
Cardiff, Sheffield, Glasgow, London
2020-02-11
Active, closed
Daiichi Sankyo
Phase 1
115
London, Manchester, Sutton
2020-02-10
Active, closed
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
NCT04042025Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA
DrugsOnasemnogene Abeparvovec-xioi·Zolgensma
Novartis Gene Therapies
Phase 3
85
London, Newcastle upon Tyne
2020-02-10
Active, closed
Hoffmann-La Roche
Phase 2/3
325
London, Northwood, Oxford, Plymouth
2020-01-29
Active, closed
Perspectum
Observational
135
Liverpool, Oxford, London
2020-01-27
Recruiting
Eli Lilly and Company
Phase 2
105
London, Manchester
2020-01-22
Active, closed
Advanced Accelerator Applications
Phase 3
226
Bristol, London, Sheffield
2020-01-08
Active, closed
USWM CT, LLC
Phase 2
103
London, Manchester
2019-12-31
Active, closed
Pfizer
Phase 3
1,068
London
2019-12-30
Recruiting
Amgen
Phase 3
24
Glasgow, Leeds, London, Southampton
2019-12-20
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Afatinib·Sotorasib
Amgen
Phase 1
610
London
2019-12-17
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
240
Lincoln, London, Oxford
2019-12-16
Active, closed
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
RECORDATI GROUP
Observational
429
Truro, Carlisle, Gillingham, London, Salford, Airdrie, Newcastle upon Tyne, Middlesbrough
2019-12-12
Active, closed
LAM561 With RT and TMZ for Adults With Glioblastoma
NCT04250922Primary Glioblastoma, Glioblastoma Multiforme
DrugLAM561
Laminar Pharmaceuticals
Phase 2/3
144
Newcastle, Birmingham, Cambridge, London
2019-12-01
Recruiting
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
Abbott Medical Devices
Observational
1,000
Liverpool, Bristol, Glasgow, London
2019-11-26
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
Bellshill, Birmingham, Cardiff, Hexham, London, Londonderry, Manchester
2019-11-26
Active, closed
Foundry Innovation & Research 1, Limited (FIRE1)
Not applicable
50
Bournemouth, Glasgow, Leicester, London, Portsmouth, Southampton
2019-11-22
Active, closed
RhoVac APS
Phase 2
180
Liverpool, London, Nottingham, Southampton
2019-11-19
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Truro, Plymouth, Sutton, Cardiff, London
2019-11-13
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Belfast, London, Sheffield
2019-11-13
Active, closed
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
DrugsNuzefatide pevedotin·Opdivo·Nivolumab
BicycleTx Limited
Phase 1/2
288
London, Manchester, Cambridge, Leeds, Newcastle upon Tyne
2019-11-07
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Sutton, Liverpool, London
2019-11-04
Active, closed
AstraZeneca
Phase 3
140
Cambridge, Leicester, London, Portsmouth
2019-10-29
Recruiting
GlaxoSmithKline
Phase 1/2
184
Birmingham, Cardiff, Glasgow Strathclyde, London, Manchester, Nottingham, Southampton
2019-10-25
Active, closed
Nouscom SRL
Phase 1/2
115
London
2019-10-21
Active, closed
Novo Nordisk A/S
Phase 3
134
Birmingham, London, Manchester, Nottingham, Sheffield
2019-10-21
Active, closed
Replimune, Inc.
Phase 1
36
Bebington, London, Oxford
2019-10-17
Active, closed
Eli Lilly and Company
Phase 3
30
Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield
2019-10-16
Active, closed
AstraZeneca
Phase 4
75
Cambridge, Headington, Leicester, Liverpool, London, Wythenshawe
2019-10-08
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Newcastle upon Tyne, Cardiff, London
2019-10-03
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Truro, Edinburgh, Birmingham, London, Manchester, Sutton
2019-10-02
Active, closed
NeuroDerm Ltd.
Phase 3
381
London, Newcastle, Plymouth
2019-09-30
Recruiting
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
NCT04873258Healthy, Fatty Liver, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Richmond Research Institute
Observational
2,000
London
2019-09-27
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Glasgow, London
2019-09-26
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
London, Newcastle upon Tyne, Glasgow
2019-09-23
Active, closed
Applied Therapeutics, Inc.
Phase 3
675
Dundee, Glasgow, Leicester, London, Manchester
2019-09-20
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
2019-09-18
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Plymouth, Leicester, London, Southampton, Blackpool, Liverpool, Wolverhampton
2019-09-06
Active, closed
Pfizer
Phase 3
896
London, Yeovil
2019-09-05
Active, closed
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
NCT04079166Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
DrugsDNA vaccine·ImmunoBody
Scancell Ltd
Phase 2
173
Cambridge, Cardiff, Leeds, London, Manchester, Northwood, Nottingham, Oxford
2019-08-19
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2019-08-15
Active, closed
USWM CT, LLC
Phase 2
52
London, Manchester
2019-08-13
Active, closed
Hoffmann-La Roche
Phase 1/2
498
Leicester, London
2019-08-13
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Aberdeen, Leeds, London, Oxford, Sutton in Ashfield
2019-08-12
Active, closed
Hoffmann-La Roche
Phase 3
1,013
Cardiff, Glasgow, Inverness, London, London, GT LON, Nottingham, Plymouth, Salford
2019-08-12
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
London, Manchester, Southampton, Maidstone, Northwood, Edinburgh, Glasgow
2019-08-09
Active, closed
Bristol-Myers Squibb
Phase 3
839
London, Oxford
2019-08-05
Active, closed
Dentsply Sirona Implants and Consumables
Not applicable
160
London, Maidstone
2019-07-30
Active, closed
Pfizer
Phase 3
51
Newcastle upon Tyne, Glasgow, London
2019-07-29
Active, closed
Novartis Pharmaceuticals
Phase 3
253
Sheffield, Cambridge, London
2019-07-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Walsall, Canterbury, Middlesbrough, London, Stevenage, Edinburgh, Metropolitan Borough of Wirral, Truro
2019-07-24
Active, closed
Tesaro, Inc.
Phase 3
785
Brighton, Cambridge, London, Truro
2019-07-18
Active, closed
IMPEDE and IMPEDE-FX Embolization Plug Registry
NCT04044443Peripheral Vascular Embolization
Shape Memory Medical, Inc.
Observational
108
London
2019-07-09
Active, closed
Novo Nordisk A/S
Phase 2
62
Hull, Liverpool, London, Manchester
2019-07-04
Active, closed
AstraZeneca
Phase 3
923
Edinburgh, London, Sheffield, Surrey, York
2019-06-25
Active, closed
Exelixis
Phase 3
855
Cambridge, Glasgow, London, Manchester
2019-06-25
Active, closed
Novartis Pharmaceuticals
Phase 2
121
London
2019-06-24
Active, closed
W.L.Gore & Associates
Not applicable
102
London
2019-06-17
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
36
London
2019-06-13
Active, closed
BioMarin Pharmaceutical
Phase 2
73
London, Sheffield
2019-06-12
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
Bristol, Cardiff, Dundee, London, Preston, Sutton, Wakefield, Wolverhampton
2019-06-11
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Plymouth, Bristol, Cardiff, Edinburgh, Glasgow, London, Manchester
2019-06-04
Recruiting
HighLife SAS
Not applicable
120
Belfast, Brighton, Edinburgh, Leeds, Leicester, London, Oxford
2019-05-28
Active, closed
Nuvaira, Inc.
Not applicable
464
London
2019-05-23
Active, closed
Imara, Inc.
Phase 2
30
Bristol, London
2019-05-22
Active, closed
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
NCT03253263Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
OHB Neonatology Ltd.
Phase 2
295
Norwich, Chertsey, Cambridge, Coventry, Liverpool, London, Manchester
2019-05-09
Active, closed
Novo Nordisk A/S
Phase 3
1,500
Harrogate, Nottingham, Yeovil, London, Norfolk, Nuneaton, Somerset, Truro
2019-05-08
Active, closed
AstraZeneca
Phase 3
810
Bristol, Cambridge, London, Manchester, Oxford, Romford, Sheffield
2019-04-16
Active, closed
Blueprint Medicines Corporation
Phase 2
251
Glasgow, London, Metropolitan Borough of Wirral
2019-04-16
Recruiting
Allarity Therapeutics
Observational
60
Glasgow, London
2019-04-11
Recruiting
Eli Lilly and Company
Phase 3
190
Bristol, Liverpool, London, Oxford, Sheffield
2019-04-05
Active, closed
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
NCT03913143Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders
DrugSepofarsen
ProQR Therapeutics
Phase 2/3
36
London
2019-04-04
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Birmingham, Cambridge, Chorley, Hardwick, Liverpool, London, Manchester, Newcastle upon Tyne
2019-03-28
Active, closed
Eisai Inc.
Phase 3
1,906
Plymouth, Southampton, Sheffield, Birmingham, Guildford, London
2019-03-27
Active, closed
AbbVie
Phase 3
964
London, Glasgow, Stafford, Manchester, Metropolitan Borough of Wirral, Portsmouth, Torquay
2019-03-25
Active, closed
Avelumab Program Rollover Study
NCT03815643Solid Tumors
DrugAvelumab
EMD Serono Research & Development Institute, Inc.
Phase 3
205
London, Northwood, Plymouth
2019-03-22
Active, closed
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
DrugsBalstilimab·Botensilimab
Agenus Inc.
Phase 1
499
London
2019-03-20
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
DrugsZanzalintinib·Avelumab·Tecentriq·Atezolizumab
Exelixis
Phase 1
325
London, Sutton, Preston
2019-03-20
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
20
London
2019-03-20
Active, closed
Durvalumab and Tremelimumab for Pediatric Malignancies
NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
DrugDurvalumab
AstraZeneca
Phase 1/2
50
Leeds, London, Sutton
2019-03-07
Active, closed
AbbVie
Phase 3
444
London, Manchester, Metropolitan Borough of Wirral, Torquay
2019-03-07
Active, closed
AstraZeneca
Phase 3
724
Birmingham, Leeds, London, Manchester
2019-03-06
Active, closed
Deciphera Pharmaceuticals, LLC
Phase 3
453
Glasgow, Leeds, London, Sheffield
2019-02-08
Active, closed
Xenon Pharmaceuticals Inc.
Phase 2
325
London, Glasgow, Cardiff
2019-01-30
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Blackburn, Lancaster, London, Torquay, Truro, Wolverhampton
2019-01-25
Recruiting
RECORDATI GROUP
Observational
95
London, Sheffield
2019-01-15
Active, closed
Ancora Heart, Inc.
Not applicable
132
London
2019-01-15
Active, closed
Celgene
Phase 3
363
Aberdeen, Bournemouth, Headington, Oxford, Lincoln, London, Manchester
2019-01-02
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Luton, Glasgow, Sheffield, London, Oxford
2018-12-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Bristol, Nottingham, Colchester, London, Solihull, Truro
2018-12-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Inverness, London
2018-12-24
Active, closed
AstraZeneca
Phase 1/2
243
Cambridge, London, Manchester, Oxford
2018-12-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Cambridge, Cottingham-Hull, London, Sheffield
2018-12-17
Active, closed
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260Hypertension, Vascular Diseases, Cardiovascular Diseases
ReCor Medical, Inc.
Not applicable
224
Basildon, Bournemouth, Canterbury, Cardiff, London, Newcastle upon Tyne
2018-12-14
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Bristol, Cardiff, London
2018-11-28
Active, closed
Advanced Accelerator Applications
Observational
1,014
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Sheffield
2018-11-28
Active, closed
AstraZeneca
Phase 3
1,063
Edinburgh, London, Metropolitan Borough of Wirral, Nottingham, Sheffield
2018-11-16
Active, closed
AbbVie
Phase 3
265
Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth
2018-10-22
Active, closed
AstraZeneca
Phase 1
396
Cambridge, Leeds, London, Manchester, Sutton
2018-10-11
Active, closed
AbbVie
Phase 2
270
London, Nottingham, Oxford, Birmingham
2018-10-10
Recruiting
Inhibrx Biosciences, Inc
Phase 1
411
London, Manchester
2018-10-08
Active, closed
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
Active, closed
GenSight Biologics
Phase 1/2
10
London
2018-09-26
Recruiting
Hoffmann-La Roche
Phase 3
1,000
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2018-09-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
976
Cambridge, London, Sutton, Manchester
2018-09-12
Active, closed
AbbVie
Phase 3
1,242
Cambridge, Exeter, Edinburgh, London, Southampton, Barnsley, Liverpool, Newcastle upon Tyne
2018-08-28
Active, closed
Hoffmann-La Roche
Phase 3
257
London, Manchester
2018-08-16
Active, closed
Gilead Sciences
Phase 2
502
Birmingham, London, Northwood, Surrey
2018-08-13
Recruiting
Sanofi
Phase 2
51
London, Leeds, Liverpool
2018-08-09
Active, closed
AbbVie
Phase 3
1,533
London, Oxford, Dundee, Glasgow, Leeds
2018-08-09
By invitation
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
NCT03628612Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
Autolus Limited
Phase 2
500
Glasgow, London, Manchester, Newcastle upon Tyne
2018-08-02
Active, closed
Actelion
Phase 2
63
London
2018-07-23
Recruiting
Celgene
Phase 2/3
1,541
Leeds, London, Manchester Withington, Shirley Southampton
2018-07-19
Active, closed
Eli Lilly and Company
Phase 3
1,058
Bury, London, Oxford
2018-07-18
Active, closed
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
DrugsTisotumab Vedotin·Tivdak·Keytruda·Cisplatin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
350
London, Sutton
2018-06-25
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester
2018-06-21
Active, closed
Exelixis
Phase 3
837
Bristol, Cambridge, London, Manchester, Belfast
2018-06-10
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
890
Oxford, Sutton, London, Manchester
2018-05-21
Active, closed
AstraZeneca
Phase 3
1,018
Birmingham, Glasgow, Guildford, London, Sheffield, Southampton, Taunton
2018-05-14
Active, closed
GlaxoSmithKline
Phase 2
237
Bristol, Airdrie, Cardiff, London, Oxford
2018-05-03
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
DrugPetosemtamab
Genmab
Phase 1/2
560
Cambridge, London
2018-05-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc.
Observational
500
London, Newcastle upon Tyne
2018-04-23
Active, closed
Bristol-Myers Squibb
Phase 3
545
London, Manchester, Metropolitan Borough of Wirral
2018-04-18
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Barnsley, Cambridge, London
2018-04-13
Active, closed
Bristol-Myers Squibb
Phase 2/3
714
Bristol, Glasgow, Swansea, London, Inverness
2018-04-11
Active, closed
Merck Sharp & Dohme LLC
Phase 2
340
London
2018-04-09
Active, closed
AbbVie
Phase 3
1,336
Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford
2018-04-09
By invitation
USWM CT, LLC
Phase 1
250
London, Manchester, Sutton
2018-04-09
Active, closed
Janssen Research & Development, LLC
Phase 1/2
125
Lancaster, London, Nottingham
2018-04-05
Recruiting
Hoffmann-La Roche
Phase 1/2
1,132
Glasgow, London
2018-03-30
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Active, closed
AbbVie
Phase 3
747
Bath, Warrington, London, Taunton, Prescot, Belfast, Birmingham, Dudley
2018-03-21
Active, closed
Orion Corporation, Orion Pharma
Phase 1/2
204
Bedlington, Cardiff, Glasgow, Liverpool, London, Manchester, Preston
2018-03-19
Active, closed
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Active, closed
Janssen Research & Development, LLC
Phase 2
136
Bath, London, Southampton, Sutton, Truro
2018-03-02
Recruiting
Octapharma
Observational
200
Headington, Birmingham, London, Newcastle upon Tyne
2018-02-13
Active, closed
InSightec
Not applicable
92
London
2018-02-09
Active, closed
AMPLATZER PFO Occluder Post Approval Study
NCT03309332Stroke, Patent Foramen Ovale
Abbott Medical Devices
Not applicable
1,214
London
2018-01-31
Active, closed
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Active, closed
EBR Systems, Inc.
Not applicable
300
Liverpool, London, Manchester, Middlesbrough, Oxford
2018-01-17
By invitation
Astellas Institute for Regenerative Medicine
Phase 1/2
36
London
2018-01-08
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
DrugTabelecleucel
Pierre Fabre Medicament
Phase 3
115
Birmingham, London
2017-12-29
Active, closed
Pfizer
Phase 3
1,054
Plymouth, Oxford, Glasgow, Bebington, Cornwall, Liverpool, London
2017-12-18
Recruiting
LivaNova
Observational
500
Leicester, London, Newcastle upon Tyne, Wells
2017-12-14
Active, closed
Gilead Sciences
Phase 3
340
Birmingham, Hull, London, Newcastle upon Tyne, Nottingham, Plymouth, Portsmouth
2017-12-12
Active, closed
BioMarin Pharmaceutical
Phase 3
119
London, Sheffield
2017-12-12
Active, closed
Genentech, Inc.
Phase 1
181
London, Suttton
2017-11-24
Active, closed
BeiGene
Phase 3
590
Birmingham, Bournemouth, Cambridge, Canterbury, Greater Manchester, Leeds, London, Maidstone
2017-10-31
Active, closed
Endurant CHevAr New Indication Trial: ENCHANT
NCT03320252AAA - Abdominal Aortic Aneurysm
Medtronic Cardiovascular
Observational
150
London, Manchester
2017-10-26
Active, closed
Janssen-Cilag International NV
Observational
135
Cardiff, London, Salford
2017-10-25
Recruiting
Italfarmaco
Phase 2/3
206
Liverpool, Gobowen, London, Newcastle upon Tyne
2017-10-24
Active, closed
Genzyme, a Sanofi Company
Phase 2
22
London, Manchester
2017-10-12
Recruiting
Apollomics Inc.
Phase 2
497
London, Manchester, Surrey Quays
2017-09-27
Active, closed
H1 Hip Resurfacing Arthroplasty
NCT03326804Hip Osteoarthritis, Hip Necrosis, Hip Dysplasia
Embody Orthopaedic Limited
Observational
250
London
2017-09-26
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab
Replimune, Inc.
Phase 2
340
Leeds, Oxford, Glasgow, Bebington, London, Southampton
2017-09-20
Active, closed
Hoffmann-La Roche
Phase 3
382
London, Manchester, Metropolitan Borough of Wirral, Nottingham, Surrey
2017-09-20
Active, closed
Global Fenestrated Anaconda Clinical STudy
NCT03180996Abdominal Aortic Aneurysm
Vascutek Ltd.
Observational
160
Newcastle upon Tyne, Camberley, London
2017-09-11
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
DrugsCabozantinib·Tecentriq·Atezolizumab
Exelixis
Phase 1
914
Middlesex, Preston, Cardiff, London
2017-09-05
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Birmingham, Buckinghamshire, Cambridge, Liverpool, London, Sheffield
2017-08-23
Active, closed
Medtronic
Observational
1,092
Birmingham, Blackpool, Liverpool, London, Manchester, Middlesbrough, Sheffield
2017-08-21
Recruiting
Advenchen Laboratories, LLC
Phase 3
325
London
2017-08-15
Active, closed
ModernaTX, Inc.
Phase 1
161
Dundee, Sutton, London
2017-08-14
Active, closed
Eisai Inc.
Phase 1
60
Glasgow, Manchester, Sutton, London
2017-07-27
Active, closed
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 2
120
London
2017-07-26
Active, closed
Eli Lilly and Company
Phase 3
5,637
Truro, Chelmsford, London, Northwood, Blackpool, Preston, Boston, Central Middlesbrough
2017-07-12
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Sheffield, Glasgow, London, Gloucester, Oxford
2017-06-26
Active, closed
AstraZeneca
Phase 3
1,186
Leicester, London, Manchester
2017-06-01
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
DrugIbrutinib
Pharmacyclics Switzerland GmbH
Phase 4
297
Cardiff, Leeds, London, Manchester
2017-05-22
Active, closed
Eli Lilly and Company
Phase 1/2
857
London
2017-05-02
Recruiting
SpectraCure AB
Phase 1/2
66
London
2017-03-21
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
London, Manchester, Sutton
2017-03-07
Active, closed
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
NCT03069469Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor
DrugVimseltinib
Deciphera Pharmaceuticals, LLC
Phase 1/2
120
London
2017-02-16
Active, closed
ITM Solucin GmbH
Phase 3
324
London, Manchester
2017-02-02
Active, closed
Acerta Pharma BV
Phase 3
310
Birmingham, Cambridge, Canterbury, Leicester, London, Maidstone, Manchester, Southampton
2017-02-02
Active, closed
AbbVie
Phase 3
950
Bath, Exeter, Basingstoke, London, Glasgow, Birmingham, Huddersfield
2017-01-31
Active, closed
AstraZeneca
Phase 1
117
Glasgow, London, Manchester, Southampton
2016-12-28
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Bebington, Belfast, Bristol, Cambridge, Cardiff, Glasgow, London, Manchester
2016-12-22
Active, closed
Genentech, Inc.
Phase 1
200
Surrey, London
2016-12-13
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Birmingham, Edinburgh, London, Romford, Stoke-on-Trent
2016-12
Recruiting
Fosfomycin I.v. for Treatment of Severely Infected Patients
NCT02979951Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
Infectopharm Arzneimittel GmbH
Observational
1,000
Bolton, Cottingham, Dundee, Glasgow, Kilmarnock, London
2016-12
Active, closed
Janssen Research & Development, LLC
Phase 1/2
234
Glasgow, London, Manchester, Newcastle upon Tyne
2016-11-21
Active, closed
ViiV Healthcare
Phase 3
631
Birmingham, Coventry, Leeds Yorkshire, London
2016-10-27
Active, closed
Eisai Inc.
Phase 3
1,069
Bournemouth, Cardiff, Edinburgh, Glasgow, Leeds, London, Manchester
2016-10-13
Active, closed
Tesaro, Inc.
Phase 3
733
Blackburn, Edinburgh, Exeter, Glasgow, London, Portsmouth, Sheffield, Truro
2016-07-11
Active, closed
Celgene
Phase 1/2
130
Birmingham, Headington, London, Sutton (Surrey)
2016-06-03
Active, closed
Eli Lilly and Company
Phase 2
309
London, Manchester, Acton, Bebbington, Sutton
2016-05-19
Active, closed
Hoffmann-La Roche
Phase 1/2
69
London, Newcastle upon Tyne
2016-05-03
Active, closed
AstraZeneca
Phase 1/2
264
Cambridge, Dundee, Glasgow, Greater London, London, Manchester, Newcastle upon Tyne, Sutton
2016-03-17
Recruiting
Boston Scientific Corporation
Observational
300
Bristol, Glasgow, London, Newcastle upon Tyne
2016-03-07
Active, closed
Tesaro, Inc.
Phase 1
729
Newcastle upon Tyne, Aberdeen, London, Manchester, Oxford, Sutton
2016-03-07
Active, closed
REDUCER-I: An Observational Study of the Neovasc Reducer™ System
NCT02710435Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina
Shockwave Medical, Inc.
Observational
400
Bradford, Edinburgh, London
2016-03
Active, closed
ReCor Medical, Inc.
Not applicable
282
Bournemouth, London, Basildon, Exeter, Hastings, Nottingham
2016-03
Active, closed
MedImmune LLC
Phase 1/2
383
London, Sutton
2016-02-22
Active, closed
BioMarin Pharmaceutical
Phase 2
30
London
2016-01-26
Active, closed
Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product
NCT02698579Cerebral Adrenoleukodystrophy (CALD), Adrenoleukodystrophy (ALD), X-Linked Adrenoleukodystrophy (X-ALD)
Genetix Biotherapeutics Inc.
Observational
64
London
2016-01-22
Active, closed
AbbVie
Phase 3
1,629
London, Portsmouth, Warrington
2015-12-01
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Carlisle, Dundee, Glasgow, London, Newcastle upon Tyne, Oxford, Plymouth, Scunthorpe
2015-11-27
Active, closed
Hoffmann-La Roche
Phase 2
534
Cambridge, London, Manchester
2015-11-19
Active, closed
On-X Life Technologies, Inc.
Observational
510
Blackpool, Hull, London, Oxford, Southampton
2015-11-10
Active, closed
AstraZeneca
Phase 3
953
Guildford, London, Manchester, Metropolitan Borough of Wirral, Nottingham, Taunton, Wolverhampton
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,126
Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield
2015-11-02
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Birmingham, London
2015-11-02
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester
2015-07-14
Active, closed
Medtronic
Observational
3,100
Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough
2015-07
Active, closed
Acerta Pharma BV
Phase 3
535
Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro
2015-06-26
Active, closed
Eli Lilly and Company
Phase 3
545
London, Chelsea, Nottingham
2015-05-06
Active, closed
Janssen Research & Development, LLC
Phase 2
239
Blackburn, Dundee, Essex, London, Metropolitan Borough of Wirral, Plymouth, Sutton
2015-04-22
Active, closed
Medtronic Cardiovascular
Not applicable
128
Brighton, Leeds, London
2015-04
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
370
London
2015-03-19
Active, closed
ViiV Healthcare
Phase 3
371
Bournemouth, Leicester, London
2015-02-23
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Active, closed
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Partner Therapeutics, Inc.
Phase 2
250
London
2015-01
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Glasgow, Wonford, London, Sutton, Birmingham, Bristol
2014-12-17
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Ayr, Belfast, Birmingham, Edinburgh, Glasgow, London, Manchester, Metropolitan Borough of Wirral
2014-11-26
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Gloucester, Southampton, Sutton, Harrow, Leeds, Cambridge, Liverpool, London
2014-11
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Bristol, Cambridge, Coventry, London, Manchester, Oxford, Sutton, Withington
2014-10-31
Active, closed
Acerta Pharma BV
Phase 2
107
Bournemouth, Leeds, Leicester, London, Oxford, Plymouth, Southampton
2014-09-11
Active, closed
AbbVie
Observational
1,446
Derby, Sheffield, London, Southampton, Glasgow, Carshalton, Aberdeen, Birmingham
2014-08-28
Rows per page Showing 1501–2000 of 2026
Previous 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-uk/city/london?page=4

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,878 studies in total at the last sync on 07 Nov 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,026 of those studies with a site in London.

How many clinical trials are recruiting in London?

983 of the 2,026 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:15 UTC sync. A further 26 have not yet opened recruitment, 956 are active but closed to new participants, and 61 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.